<DOC>
	<DOCNO>NCT00517218</DOCNO>
	<brief_summary>To compare efficacy safety combination treatment Genasense , fludarabine , rituximab versus combination treatment fludarabine rituximab previously untreated subject CLL .</brief_summary>
	<brief_title>This Study Being Performed Evaluate Effect Genasense Efficacy Safety Rituximab/Fludarabine Combination Treatment Previously Untreated Subjects With Chronic Lymphocyctic Leukemia ( CLL )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Previously untreated subject intermediateor highrisk CLL ( modify Rai Stages IIV ) Measurable disease primarily establish National Cancer Institutesponsored Working Group ( NCIWG ) Guidelines diagnosis CLL Requiring therapy active disease , primarily define NCIWG Guidelines Eastern Cooperative Oncology Group Performance Status &lt; 2 Adequate organ function determine , 14 day prior first dose study medication Absolute Lymphocyte count &gt; 100,000/uL Prior chemotherapy therapy CLL , include allogeneic transplant Less 3 week prior major surgery time inform consent Failure recover serious adverse effect surgery History autoimmune hemolytic anemia autoimmune thrombocytopenia Active serious infection require systemic antiinfective therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>Evaluate Effect Genasense Efficacy/Safety Rituximab/Fludarabine Treatment Untreated Subjects With Chronic Lymphocyctic Leukemia</keyword>
</DOC>